JP2008546716A - 抗ＧＦＲα３抗体 - Google Patents

抗ＧＦＲα３抗体 Download PDF

Info

Publication number
JP2008546716A
JP2008546716A JP2008517215A JP2008517215A JP2008546716A JP 2008546716 A JP2008546716 A JP 2008546716A JP 2008517215 A JP2008517215 A JP 2008517215A JP 2008517215 A JP2008517215 A JP 2008517215A JP 2008546716 A JP2008546716 A JP 2008546716A
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008517215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008546716A5 (https=
Inventor
デーン エス． ウォーリー，
ダイナ ウェン−イー サー，
キャサリン ダブリュー． シーマンス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Inc
Biogen Idec Inc
Biogen Idec MA Inc
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Biogen Idec Inc, Biogen Idec MA Inc, Biogen MA Inc filed Critical Biogen Inc
Publication of JP2008546716A publication Critical patent/JP2008546716A/ja
Publication of JP2008546716A5 publication Critical patent/JP2008546716A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2008517215A 2005-06-17 2006-06-16 抗ＧＦＲα３抗体 Withdrawn JP2008546716A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69185005P 2005-06-17 2005-06-17
PCT/US2006/023821 WO2006138721A1 (en) 2005-06-17 2006-06-16 Anti-gfralpha3 antibodies

Publications (2)

Publication Number Publication Date
JP2008546716A true JP2008546716A (ja) 2008-12-25
JP2008546716A5 JP2008546716A5 (https=) 2009-07-30

Family

ID=37570787

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008517215A Withdrawn JP2008546716A (ja) 2005-06-17 2006-06-16 抗ＧＦＲα３抗体

Country Status (5)

Country Link
US (1) US20090202562A1 (https=)
EP (1) EP1896047A4 (https=)
JP (1) JP2008546716A (https=)
CA (1) CA2612417A1 (https=)
WO (1) WO2006138721A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150041664A (ko) * 2012-08-22 2015-04-16 리제너론 파마슈티칼스 인코포레이티드 GFRα3에 대한 인간 항체 및 이것의 사용 방법
JP2022527373A (ja) * 2019-04-10 2022-06-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｒｅｔを結合するヒト抗体およびその使用方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
EP4406972A4 (en) * 2021-09-24 2025-12-31 Daegu Gyeongbuk Inst Science & Tech GFRAL ANTAGONIST ANTIBODY WITH IMPROVED AFINITY, AND ITS USE
KR102864956B1 (ko) * 2021-09-24 2025-09-30 재단법인대구경북과학기술원 친화도가 개선된 gfral 길항 항체 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677135B1 (en) * 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
EP0962467A4 (en) * 1996-09-26 2002-10-30 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
EP1156062A1 (en) * 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150041664A (ko) * 2012-08-22 2015-04-16 리제너론 파마슈티칼스 인코포레이티드 GFRα3에 대한 인간 항체 및 이것의 사용 방법
JP2015532647A (ja) * 2012-08-22 2015-11-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＧＦＲα３に対するヒト抗体およびその使用方法
JP2018143252A (ja) * 2012-08-22 2018-09-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＧＦＲα３に対するヒト抗体およびその使用方法
KR102158569B1 (ko) * 2012-08-22 2020-09-22 리제너론 파마슈티칼스 인코포레이티드 GFRα3에 대한 인간 항체 및 이것의 사용 방법
JP2022527373A (ja) * 2019-04-10 2022-06-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｒｅｔを結合するヒト抗体およびその使用方法
JP7511576B2 (ja) 2019-04-10 2024-07-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｒｅｔを結合するヒト抗体およびその使用方法

Also Published As

Publication number Publication date
CA2612417A1 (en) 2006-12-28
EP1896047A4 (en) 2009-07-22
EP1896047A1 (en) 2008-03-12
WO2006138721A1 (en) 2006-12-28
US20090202562A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
JP6677466B2 (ja) Ｔｏｌｌ受容体２へのヒト化抗体およびその使用
RU2700104C2 (ru) УЛУЧШЕННЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Аβ-ПРОТОФИБРИЛЛЫ
CN107249631B (zh) 改进的il-6抗体
KR20150018533A (ko) 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
US11999790B2 (en) Anti-OX40 antibodies and uses thereof
TW202302640A (zh) 抗tl1a抗體組合物及肺中之治療方法
CN118324911A (zh) 用于治疗自身免疫病的抗ifnar1抗体
TW202246322A (zh) 包含針對類tnf配體1a(tl1a)之人類化抗體之組合物及其用途
CN113227131A (zh) 经修饰的抗体Fc及其使用方法
EP3829636A1 (en) Use of glucagon receptor antagonists with immunotherapeutic agent
BR112021007134A2 (pt) terapia combinada para câncer
EP4375295A1 (en) Antibody drug for prevention or treatment of autoimmune diseases
RU2539034C2 (ru) Лечение рассеянного склероза
CN112079922B (zh) 抗人p40蛋白域抗体及其用途
WO2017122666A1 (ja) 抗Ｍｙｌ９抗体
JP2008546716A (ja) 抗ＧＦＲα３抗体
JP2012131825A (ja) Ｔｈ２介在性状態の治療のためのＫＩＭ−１抗体
US20240366777A1 (en) Anti-folate receptor conjugate combination therapy with bevacizumab
TW202330027A (zh) 抗ｃｄ－４７抗體製劑
US20250163168A1 (en) Novel antibodies and antibody conjugates for the treatment of metabolic disorders
CN119110807A (zh) 抗cd40抗体及其用途
HK40093161A (zh) 抗ctla-4抗体药物组合物及其用途
HK40117288A (zh) 抗cd40抗体及其用途
NZ794702A (en) Anti-OX40 antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090610

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20101018

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20101102